Background {#Sec1}
==========

Breast cancer as a multifactorial disease is the most diagnosed cancer among women worldwide \[[@CR1]\]. The incidence of breast cancer in women would be higher in developed countries due to the great heterogeneity in terms of polymorphism frequency, proportion of deletions and insertions, but with the recent improvements and availability of diagnostic infrastructure in LMICs, the detection rate has continued to increase. Over the past decade, the number of women globally affected has increased, but data from LMICs are still limited \[[@CR2]\]. With the advent of genomics, dramatic advances have been made in breast cancer research. Recent report showed that in addition to clinical, lifestyle and environmental risk factors, an individual's genetic background plays a crucial role in the development of breast cancer \[[@CR3]\]. Several genes have been shown to be associated with an increased risk of breast cancer, such as damaged DNA repair genes (*BRCA1 and BRCA2), tumor protein p53* (*TP53*), *Checkpoint kinase 2 (CHEK2), methylenetetrahydrofolate reductase* (*MTHFR*)*, fibroblast growth factor receptor 2 (FGFR2) and glutathione S-transferase mu 1* (*GSTM1*) \[[@CR4]\]. *TP53*, a tumor suppressor gene, is involved not only in the development of breast cancer, but also in the development of other human cancers. Indeed, this gene plays a significant role in the response to stress. The protein TP53, also called the genome guardian, is a transcription factor that controls the expression of many genes involved in cell cycle regulation, DNA repair, cell death and senescence \[[@CR5]--[@CR8]\]. The great heterogeneity reported in the *TP53* in breast cancer may be linked to the geographic origin and ethnic differences of patients \[[@CR8]--[@CR10]\].

The *TP53* is located on the chromosome 17p13.1 \[[@CR11]\] and consists of 12 exons (<https://www.ncbi.nlm.nih.gov/gene/7157>). It is highly polymorphic both in exonic and intronic regions with more than 200 polymorphisms (<http://www-p53.iarc.fr/>). Of these, p.Arg72Pro, p.Pro47Ser and PIN3 16-bp duplication of *TP53* are the most studied polymorphisms because of their critical roles in modifying the function and/or expression of TP53 \[[@CR7], [@CR12]\]. Sequence changes in the coding region affected by 16 bp duplication of PIN3 may result in impaired function and expression of p53 \[[@CR13]\]. This disturbance is involved in the etiopathology of many cancers, including breast cancer \[[@CR14], [@CR15]\]. Several studies around the world have found an association between the polymorphisms of this gene and the development of breast cancer \[[@CR16], [@CR17]\], while others have found no effect \[[@CR18]--[@CR20]\]. It has been reported in developed countries that individuals harboring the A2A2 genotype or 16-bp duplication in intron 3 of *TP53* are at increased risk of breast cancer \[[@CR21], [@CR22]\]. However, very few studies have been performed in Africa populations \[[@CR19]\], especially in Mali. The literature review revealed that the association between the PIN3 16 bp duplication polymorphism and the risk of breast cancer has not been evaluated in our population. Consequently, we carried out the present work in order to understand firstly the relation between the duplication PIN3 16 bp and the development of breast cancer in the Malian population and secondly to carry out a comparative meta-analysis of different studies around the world to better estimate the risk of breast cancer.

The literature review showed that the relationship between PIN3 16-bp duplication polymorphism and the risk of breast cancer has not been evaluated in our population. Therefore, we carried out the present work in order to understand firstly the relation between PIN3 16-bp duplication and the risk of breast cancer in the Malian population and secondly to perform a comparative meta-analysis of different studies around the world better to estimate the risk of breast cancer.

Methods {#Sec2}
=======

Case control study {#Sec3}
------------------

### Subject selection and sample collection {#Sec4}

The study was approved by the ethics committee of the Faculty of Medicine and Odontostomatology (2018/63/CE/FMPOS) at the University of Sciences, Techniques and Technologies of Bamako (USTTB). The study was explained to each participant prior being asked to sign the approved Informed Consent.

Sixty women (mean age 43.72 ± 3.14) with clinically and histologically diagnosed breast cancer and 60 age-matched apparently healthy women (mean age 43.90 ± 2.92) from the general population were recruited at the University Hospital Center (CHU) of Point G in Bamako, Mali, between July 2018 and July 2019. All cases had early stage cancer (stage II). Clinico-pathological parameters including age at diagnosis, localization, use of contraceptive, menopausal status, parity, breastfeeding, family history of breast cancer, history of benign breast disease, obesity, smoking, histological type, tumor size, nodal involvement and metastasis were collected from each patient's medical record. In the control group, the inclusion criteria were all Malian women aged of 18 years or over coming from the general population of whom no chronic disease has ever been diagnosed (such as cancer, diabetes, etc.) and having accepted informed consent. Healthy subjects with a history of breast cancer, chronic diseases such as diabetes, or other types of cancer were excluded as controls. A total Five milliliter of peripheral blood was collected from each participant in an EDTA tube for thegenotyping analysis of PIN3 16-bp duplication polymorphism of *TP53*.

### Genotyping of PIN3 16-bp duplication {#Sec5}

Qiagen's GentaPuregene Extraction Kit was used to extract the genomic DNA from white blood cells. DNA quantity and quality were determined by spectrophotometer. Genotyping of PIN316-bp duplication polymorphism was performed by allele specific PCR (AS-PCR) using published primers previously described \[[@CR17], [@CR19], [@CR23], [@CR24]\]. A final reaction volume of 25 μl containing 12.8 μl buffer, 1.5 μl MgCl2, 1.5 μl dNTPs, 1.0 μl primers, 2.0 μl Taq DNA polymerase, and 2.0 μl genomic DNA was used to amplify the PIN3 16-bp duplication of the *TP53*. PCR amplification conditions were previously described by Maarouf and al \[[@CR19]\].. The PCR products after electrophoresis on a 4.5% agarose gel showed a fragment of 119 bp for the A1 allele (wild type or no duplication) and a fragment of 135 bp for the A2 allele (Insert or 16-bp duplication).

### Statistical analysis {#Sec6}

SPSS 11.0 was used to analyze the data. Chi-square tests (two-sided) were performed to evaluate the correlation between the PIN3 16-bp duplication and the clinical and histological features. Hardy-Weinberg equilibrium for the PIN3 16-bp duplication genotype distribution of *TP53* was tested by Chi2 analysis with exact probability. An odds ratio (OR) test with 95% confidence interval (CI) and P \<0.05 was used to determine the association between PIN3 16-bp duplication polymorphism of *TP53* and the risk of breast cancer, according to the different genetic models (dominant: A1A2 + A2A2 vs. A1A1, recessive: A2A2 vs. A1A2 + A1A1 and additive: A2 vs. A1). The *P* value \< 0.05 was considered significant.

Meta-analysis study {#Sec7}
-------------------

### Literature search {#Sec8}

The keywords "*TP53*", "Intron 3 Ins16 bp or PIN3 16-bp duplication"; "Polymorphism or mutation or genes" and "breast cancer" were used to perform a literature search of Pubmed, Harvard University Library, Genetics Medical Literature Database, Genesis Library and Web of Science. Only articles published in English were retained. Additional articles were identified by examining the references cited in articles and reviews retained from the search.

### Article inclusion c***riteria*** {#Sec9}

The criteria for selecting the articles were as follows: (1) Results reported about a case-control study, study published as an original study evaluating the association between PIN3 16-bp duplication polymorphism of *TP53* and the risk of breast cancer; (2) No deviation from Hardy-Weinberg Equilibrium (HWE) in controls; (3) No influence on the pooled odds ratio (OR) and *p*-values (Fig. [1](#Fig1){ref-type="fig"}); and (4) Full text available. Two investigators independently reviewed the abstracts of the initial search and assessed each article for inclusion in the meta-analysis. Fig. 1Flow chart of meta-analysis for exclusion/inclusion of studies

### Data ext***raction*** {#Sec10}

The following data were extracted from all eligible studies: first author's name, year of publication, study population, sample size, genotypic and allelic distribution by two independent investigators (add the initials of the two extractors). These data were compared to find a consensus. A third investigator resolved any conflict.

Statistical analysis {#Sec11}
--------------------

Review Manager Software was used to analyze the data. The Chi-squared test with the value of *P* \< 0.05 was carried out to evaluate the Hardy-Weinberg equilibrium in the controls. The association of PIN3 16-bp duplication polymorphism with the risk of breast cancer in the dominant, recessive and additive models was measured by ORs with 95% CI. An inconsistency (I^2^) test was performed to detect heterogeneity \[[@CR25]\]. If I^2^ \<50% (absence of heterogeneity), the fixed effect model (FEM) was chosen as a pooling method; otherwise, if I^2^ \>50% (presence of heterogeneity), the random effect model (REM) was maintained. The addition and/or deletion of any study that modifies the value of the pooled OR ± 1 was done to assess the sensitivity of the meta-analysis. The funnel curve was used to identify the publication bias.

Results {#Sec12}
=======

Case control study {#Sec13}
------------------

We evaluated the association between PIN3 16-bp duplication polymorphism of *TP53* and the risk of breast cancer in Malian women. The demographic, clinical, and pathological characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. The mean age of cases and controls was 43.72 ± 3.14 and 43.90 ± 2.92 years, respectively. Most of the patients had cancer in the left breast. Multiparity was reported in 75.5% of cases, breastfeeding in 88.3%, no family history of breast cancer in 86.6%, no history of benign breast disease in 90.0%, absence of obesity in 68.3% and no history of smoking in 88.3% of the cases. Invasive ductal carcinoma forms were more prevalent than any others histological form of breast cancer (Table [1](#Tab1){ref-type="table"}). Patients with PIN3 16-bp duplication (A2A2) of *TP53* were more likely to have an invasive ductal carcinoma form, T3 stage tumor size, node involvement (N0 and N1), and M0 metastasis status compared to patients with the A1A1 or A1A2 genotype. We found no correlation between the PIN3 16-bp duplication polymorphism and the clinical features of participants except histological type (*p* = 0.04). Table 1Distribution of the PIN3 16-bp duplication polymorphism of *TP5*3 according to the clinicopathological characteristics in Malian breast cancerClinical parameterN (%)PIN3 16-bp duplicationX^**2**^*P* valueA1A1%A1A2%A2A2%**Mean age at diagnosis**43.72 ± 3.142.41\*0.12  ≤ 40 years of age29 (48.3)11 (37.9)12 (41.4)6 (20.7)  \> 40 years of age31 (51.7)16 (51.6)13 (41.4)2 (6.5)**Localization**1.980.74 Right breast19 (31.7)7 (36.8)9 (47.4)3 (15.8) Left breast37 (61.7)19 (51.4)14 (37.8)4 (10.8) Bilateral4 (6.6)1 (25.0)2 (50.0)1 (25.0)**Use of contraceptives**0.56\*0.45 No45 (75.0)18 (40.0)25 (55,6)2 (4.4) Yes15 (25.0)9 (60.0)--6 (40.0)**Menopausal status**3.150.53 Pre-menopausal11 (18.3)6 (54.5)4 (36.4)1 (9.1) Post-menopausal20 (33.3)10 (50.0)9 (45.0)1 (5.0) Fertile women29 (48.3)11 (37.9)12 (41.4)6 (20.7)**Parity**7.330.12 Nulliparity6 (10.0)--5 (83.3)1 (16.7) Primiparity9 (15.0)3 (33.3)4 (44.4)2 (22.2) Multiparity45 (75.5)24 (53.3)16 (35.6)5 (11.1)**Breastfeeding**0.50\*0.48 Yes53 (88.3)26 (49.1)19 (35.8)8 (15.1) No7 (11.7)1 (14.3)6 (85.7)--**Family history of BC**0.64\*0.42 Yes8 (13.3)4 (50.0)4 (50.0)-- No52 (86.7)23 (44.2)21 (40.4)8 (15.4)**Personal history of benign breast disease**1.69\*0.19 Yes6 (10.0)4 (66.7)2 (33.3)-- No54 (90.0)23 (42.6)23 (42.6)8 (14.8)**Obesity**0.430.81 Yes19 (31.7)8 (42.1)9 (47.4)2 (10.5) No41 (68.3)19 (46.3)16 (39.0)6 (14.6)**Smoking**0.20\*0.65 Passive smoking7 (11.7)3 (42.9)4 (57.1)-- No53 (88.3)24 (45.3)21 (39.6)8 (15.1)**Histological type**4.14\*0.04 Invasive ductal carcinoma56 (93.3)23 (41.1)25 (44.6)8 (14.3) Others4 (6.7)4 (100.0)----**Tumor size**5.630.46 T11 (1.7)--1 (100.0)-- T210 (16.7)5 (50.0)5 (50.0)-- T341 (68.3)18 (43.9)15 (36.6)8 (19.5) T48 (13.3)4 (50.0)4 (50.0)--**Nodal involvement** N036 (60.0)16 (44.4)16 (44.4)4 (11.1)6.050.41 N116 (26.7)5 (31.3)7 (43.8)4 (25.0) N27 (11.7)5 (71.4)2 (28.6)-- N31 (1.7)1 (100.0)----**Metastasis**0.91\*0.34 M055 (91.7)24 (43.6)23 (41.8)8 (14.5) M15 (8.3)3 (60.0)2 (40.0)--*X*^*2*^ Chi-squared test, *P p-*value, *\** Chi-squared test two-sided, *N* Number, *BC* Breast cancer, *A1A1* Wild-type, *A1A2* heterozygous, *A2A2* homozygous mutant, *%* Percentagwe, Other histological type: Glycogen-rich clear cell carcinoma, lobular carcinoma in situ, Moderately differentiated adenocarcinoma and infiltrating adenocarcinoma.

### PIN3 16-bp duplication polymorphism of *TP53* and breast Cancer risk {#Sec14}

Table [2](#Tab2){ref-type="table"} shows the distribution of PIN3 16-bp duplication polymorphism of the *TP53* in the cases according to the genetic models. The genotypic distribution PIN3 16-bp duplication polymorphism did not deviate from the Hardy-Weinberg equilibrium both in the cases (X^2^ = 0.33, *p* = 0.57) and in the controls (X^2^ = 2.76, *p* = 0.10). The heterozygous genotype (A1A2) was associated with an increased risk of breast cancer with (OR = 2.25, 95% CI = 1.01--5.01 and *p* = 0.04). When we extended the analysis to the different genetic models, we noted that the dominant model (A1A2 + A2A2 vs. A1A1: OR = 2.26, 95% CI = 1.08--4.73, *p* = 0.02) and the additive model (A2 vs A1: OR = 1.87, 95% CI = 1.05--3.33, *p* = 0.03) of PIN3 16-bp duplication polymorphism was significantly associated with the risk of breast cancer (Table [2](#Tab2){ref-type="table"}). Table 2Association of genetic models of PIN3 16-bp duplication polymorphism of *TP53* with breast cancer riskGenotype/AlleleCasesControlsOR (95% CI)*PN* = 60N = 60**A1A1**27 (45.0)39 (65.0)Reference**A1A2**25 (41.7)16 (26.7)2.25 (1.01--5.01)0.04**A2A2**8 (13.3)5 (8.3)2.31 (0.68--7.83)0.17**A2A2 + A1A2**33 (55.0)21 (35.0)2.26 (1.08--4.73)0.02**A1A1 + A1A2**52 (86.7)55 (91.7)Reference**A2A2**8 (13.3)5 (8.3)1.69 (0.52--5.50)0.38**A1**79 (65.8)94 (78.3)Reference**A2**41 (34.2)26 (21.7)1.87 (1.05--3.33)0.03*N* Number, *CI* confidence Interval, *P p*-value, A2A2 + A1A2 vs. A1A1: Dominant model, A2A2 vs. A1A1 + A1A2: Recessive model; A2 vs. A1: Additive model.

Meta-analysis study {#Sec15}
-------------------

### Characteristics of included studies {#Sec16}

A total of 19 articles reporting case-control studies that investigated PIN3 16-bp duplication polymorphism and breast cancer risk and meeting the inclusion criteria were selected to perform the meta-analysis (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}). Thirty studies that have not addressed PIN3 16-bp duplication of *TP53,* 6 studies deviating from HWE, as well as 2 studies \[[@CR38], [@CR39]\] which influenced the OR and *p* values pooled were excluded (Fig. [1](#Fig1){ref-type="fig"}). Table 3Summary of studies included in meta-analysisReferencePopulationCasesControlsNA1A1A1A2A2A2NA1A1A1A2A2A2HWEPresent studyMali602725860391650.10Akkiprik et al. 2009 \[[@CR18]\]Turkey9759353107614330.15Buyru et al. 2007 \[[@CR26]\]Turkey1158328463471510.87Cherdyntseva et al. 2012 \[[@CR27]\]Russia2962276811961455010.13Costa et al. 2008 \[[@CR17]\]Portugal19112256132161476540.29De Vecchi et al. 2008 \[[@CR28]\]Italy350233103143522568790.62Gaudet et al. 2007 \[[@CR29]\]USA (M)57840415717390272108100.85Gohari-Lasaki et al. 2015 \[[@CR23]\]Iran10053389100603730.34Guleria et al. 2012 \[[@CR30]\]India804330780532520.64Hao et al. 2018 \[[@CR31]\]Chine2542302402522272500.41Hrstka et al. 2009 \[[@CR32]\]Island11781324108812430.46Morten et al. 2019 \[[@CR20]\]Australia13049862892943632510470.67Pouladi et al. 2014 \[[@CR33]\]Iran221135691717010751120.10Sharma et al. 2014 \[[@CR7]\]India20013452142001375580.41Suspitsin et al. 2003 \[[@CR34]\]Russia529408108132491875660.47Trifa et al. 2010 \[[@CR35]\]Tunisia15998565132864150.97Vymetalkova et al. 2015 \[[@CR36]\]Czech70547416424611421172180.93Wang-Gohrke et al. 2002 \[[@CR16]\]Germany56337017320549391145130.92Weston et al. 1997 \[[@CR37]\]USA (M)99603631851275440.52*M* Mixed, *N* Number

### Quantitative analysis {#Sec17}

This meta-analysis showed a significant association between PIN3 16-bp duplication polymorphism and breast cancer risk in recessive (Fixed effect model (FEM): OR = 1.46, 95% CI = 1.15--1.85; *p* = 0.002) and additive (FEM: OR = 1.11, 95% CI = 1.02--1.19; *p* = 0.01) models, but not in the dominant model (FEM: OR = 1.07, 95% CI = 0.98--1.17; *p* = 0.15). Figures [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, and [4](#Fig4){ref-type="fig"}, show the forest plots of OR for breast cancer in the dominant, recessive and additive models of PIN3 16-bp duplication polymorphism of the *TP53*, respectively. Figure [2](#Fig2){ref-type="fig"}**.**Fig. 2Forest plots of the relationship between PIN3 16-bp duplication polymorphism of the *TP53* and breast cancer in the dominant model. The black diamond denotes the pooled OR; black squares indicate the OR in each study with square sizes inversely proportional to the standard error of the OR; and horizontal lines represent the 95% CIFig. 3Forest plots of the relationship between PIN3 16-bp duplication polymorphism of the *TP53* and breast cancer in the recessive model. The black diamond denotes the pooled OR; black squares indicate the OR in each study with square sizes inversely proportional to the standard error of the OR; and horizontal lines represent the 95% CIFig. 4Forest plots of the relationship between PIN3 16-bp duplication polymorphism of the *TP53* and breast cancer in the additive model. The black diamond denotes the pooled OR; black squares indicate the OR in each study with square sizes inversely proportional to the standard error of the OR; and horizontal lines represent the 95% CI

### Sensitivity analysis {#Sec18}

The stability of the results was assessed by a sensitivity analysis. We have noted a significant association between the PIN3 16-bp duplication polymorphism and the risk of breast cancer in the recessive (Fig. [3](#Fig3){ref-type="fig"}) and additive (Fig. [4](#Fig4){ref-type="fig"}) models, except the dominant model (Fig. [2](#Fig2){ref-type="fig"}), Furthermore, the one by one elimination of eligible studies did not influence the values of the pooled OR effect in the different genetic models.

### Sources of heterogeneity {#Sec19}

After the non-inclusion of articles with HWE-deviation in controls, we noted a lack of heterogeneity in the dominant (**I**^**2**^ = 19%, *P* = 0.23), recessive (**I**^**2**^ = 0%, *P* = 0.94) and additive (**I**^**2**^ = 11%, *P* = 0.32) models between PIN3 16-bp duplication polymorphism and breast cancer risk (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, and [4](#Fig4){ref-type="fig"}).

### Publication Bias {#Sec20}

A funnel plot was used to assess publication bias. After the elimination of studies that did not meet the inclusion criteria followed by the sensitivity analysis, no publication bias was observed in the recessive and additive models. However, a slight asymmetry was detected in the dominant model (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Funnel plots of **a** dominant, **b** recessive and **c** additive models precision by OR

Discussion {#Sec21}
==========

n the present study, we noted a positive correlation of the PIN3 16-bp duplication polymorphism of *TP53* with the histological type of breast cancer. Similar results have been found in the Iranian population by Faghani et al. who reported a correlation between invasive ductal breast cancer and the PIN3 duplication polymorphism at 16 bp \[[@CR40]\]. Contrary to our observations, studies carried out in the Moroccan, Croatian and Czech populations have not found any link between histological types and mutations in this gene \[[@CR19], [@CR32], [@CR38]\]. These contradictory results may be explained by the ethnic and geographic origin.

Our results show that the PIN3 16-bp duplication polymorphism is significantly linked to the breast cancer risk in the Malian population.

We found that heterozygous, dominant and A1A2 additive models were significantly associated with an increased risk of breast cancer. However, the results of various studies regarding the association between the PIN3 16-bp duplication of *TP53* and the risk of breast cancer are contradictory. Similar to our results, Faghani et al. and Wu et al. reported that the A1A2 genotype is associated with the risk of breast cancer \[[@CR40], [@CR41]\] On the other hand, others studies have found no association between this genotype and the risk of breast cancer \[[@CR18], [@CR38], [@CR39]\]. However, we noted that the A2A2 genotype was not associated with the development of breast cancer in our population. This observation was similar to those previously reported by in Morocco \[[@CR19]\], in Iran \[[@CR40]\], and Poland \[[@CR42]\] but contradictory with the result obtained in Portugal \[[@CR17]\]. In addition, we noted that the A2 allele was associated with the risk of breast cancer, which was consistent with the results of many authors \[[@CR30], [@CR40]\] but different from the results reported by others \[[@CR31], [@CR36]\]. The differences between studies may be explained by several factors such as sample size, race, ethnic differences, genetic background, environmental factors and heterogeity between the studies.

The meta-analysis, which included 6018 breast cancer patients and 4456 controls revealed an increased-risk of breast cancer with the recessive and additive models of PIN3 16-bp duplication. Two previous meta-analyzes, one covering 19 studies with 4479 cases and 4683 controls \[[@CR41]\] and the other covering 9 studies with 2715 cases and 2595 controls \[[@CR21]\] showed that the recessive model was associated with the risk of breast cancer. However, another meta-analysis of 6 studies with 2018 cases and 1748 controls revealed an inverse association \[[@CR22]\], but the number of studies included and the sample size for this study were relatively small. Compared to our results, all these meta-analyzes found a significant genetic association between the additive model and breast cancer \[[@CR21], [@CR22], [@CR41]\]. The mechanism associating A2 with breast cancer is not yet fully established, certain factors have been discussed. There is some evidence linking A2 status of differential expression of different p53 isoforms in lymphoblastoid cell lines, thereby causing alteration in mRNA \[[@CR13], [@CR43], [@CR44]\]. Indeed, the influence of A2 allele on the alternative splicing of p53 protein causes an instability of the transcripts or proteins with modified functions. Many investigators have reported the existence of linkage disequilibrium between 6-bp duplication and other variants of *TP53* such as codon 72 or p.Arg72Pro, intron 6 \[[@CR31], [@CR45]\]. The codon 72 Arg/Pro, intron 3 16-bp duplication and intron 6 G \> A *TP53* haplotype was associated with the ability to repair DNA in lymphoblastic cell lines and apoptic reduction \[[@CR21], [@CR46]\]. Thus, the polymorphisms of *TP53* could affect the activity of *p53* by triggering the process of carcinogenesis.

This study has some limitations such as small sample size, lack of hormonal receptors tests and subgroup analyzes in the meta-analysis. Another limitation is the collection of data limited to the demographic parameters and history of the disease in controls.

Conclusions {#Sec22}
===========

The present study made it possible to establish for the first time the distribution of alleles and genotypes of PIN3 16-bp duplication polymorphism of *TP53* in the Malian population and to understand the relationship between this gene and the risk of breast cancer. Our results have shown that this polymorphism is not only associated with the histological type, but also is with the risk of breast cancer in Malian population. In addition, the meta-analysis carried out confirmed our findings.
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